Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Genetic Signatures Ltd. Business Overview & Revenue Model
Genetic Signatures Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.08M | 15.90M | 9.77M | 16.94M | 35.42M | 28.28M |
| Gross Profit | -12.87M | 7.78M | 4.31M | -12.74M | 7.21M | 4.27M |
| EBITDA | -15.38M | -16.08M | -19.82M | -13.14M | 4.70M | 3.22M |
| Net Income | -11.27M | -20.10M | -17.86M | -14.05M | 3.06M | 1.76M |
Balance Sheet | ||||||
| Total Assets | 49.04M | 54.63M | 67.29M | 49.08M | 59.65M | 54.05M |
| Cash, Cash Equivalents and Short-Term Investments | 29.87M | 31.30M | 36.25M | 16.35M | 36.90M | 30.12M |
| Total Debt | 653.00K | 791.00K | 1.22M | 0.00 | 34.00K | 399.00K |
| Total Liabilities | 4.95M | 4.54M | 6.18M | 6.16M | 4.85M | 4.71M |
| Stockholders Equity | 44.09M | 50.09M | 61.10M | 42.91M | 54.80M | 49.34M |
Cash Flow | ||||||
| Free Cash Flow | -10.67M | -13.19M | -14.91M | -20.55M | 6.82M | -784.00K |
| Operating Cash Flow | -9.60M | -12.29M | -10.12M | -12.45M | 9.81M | 4.20M |
| Investing Cash Flow | -13.57M | -24.30M | -4.79M | -8.09M | -2.99M | -4.98M |
| Financing Cash Flow | -455.00K | 7.79M | 34.81M | -23.00K | -101.00K | -190.00K |
Genetic Signatures Ltd. Technical Analysis
Genetic Signatures Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$61.01M | 10.72 | 98.18% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$218.13M | -7.39 | -111.23% | ― | 12.96% | 40.81% | |
45 Neutral | AU$44.17M | -2.45 | -97.79% | ― | ― | 23.85% | |
43 Neutral | AU$60.85M | -4.75 | -501.54% | ― | ― | 56.42% | |
41 Neutral | AU$22.03M | -2.23 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$47.86M | -3.01 | -37.78% | ― | 2.33% | 12.50% |
Genetic Signatures Ltd. Corporate Events
Genetic Signatures Ltd., an ASX-listed molecular diagnostics firm headquartered in Sydney, focuses on PCR-based infectious disease testing using its proprietary 3base technology. The company serves pathology providers and hospitals with gastroenteric, respiratory and vaccine-preventable infection panels, supported by teams in Australia, the U.S. and the U.K., and operates under ISO 13485 with key regulatory approvals.
In its latest strategic outline for 1H FY26, the company emphasises a growth plan built around discovering previously undetected pathogens, improving diagnostic precision and supporting more confident treatment decisions. Management is targeting expansion across domestic and international markets and the development of new products, positioning the business to broaden its clinical footprint and enhance competitiveness in the molecular diagnostics sector.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.11 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Limited has notified the market of the cessation of certain securities following the lapse of conditional rights attached to two option classes. A total of 247,500 options under the GSSAB code and 40,000 options under the GSSAC code have expired as the conditions for their exercise were not satisfied, resulting in a reduction of potential future dilution for existing shareholders and a modest simplification of the company’s capital structure.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.13 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Limited has appointed non-executive director Anne Lockwood as interim Managing Director for six months, bolstering its leadership with more than 30 years’ experience in finance, risk management, M&A and capital markets, and deferring the hire of a permanent CFO during her tenure. Working closely with recently appointed CEO Maria Halasz, Lockwood’s interim role is intended to provide strong financial oversight, ensure continuity and cost discipline following recent senior departures, and support the execution of the company’s strategy from a position of strength, with the board emphasising reduced key personnel costs and a continued focus on maximising shareholder returns.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.13 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Limited has appointed experienced life sciences executive Maria Halasz as Chief Executive Officer, effective 2 March 2026, as the company positions itself for its next phase of international growth. Halasz, who has more than two decades of leadership, capital markets and commercialisation experience, including 14 years as CEO and Managing Director of ASX-listed Anagenics, is expected to strengthen Genetic Signatures’ ability to translate its molecular diagnostics innovation into commercial outcomes, deepen investor engagement and support the scaling of its global footprint, while the company continues its search for a permanent Chief Financial Officer and sets a performance-linked remuneration structure for the new CEO.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures reported unaudited second-quarter FY26 sales of $3.3 million, reflecting a seasonal downturn in respiratory testing in Australia, with revenue contributions now coming from Australia, EMEA and the US and a rising share from international markets. Customer receipts reached $4.6 million and net operating cash inflow was $1.8 million, bolstered by an Australian R&D tax incentive, leaving the company with a strong total cash and term deposit position of $29.7 million at 31 December 2025 to fund ongoing operations and development. Operationally, the company advanced implementation of its EasyScreen™ Gastrointestinal Parasite Detection Kit at three initial US customer sites that are now acting as reference centres to drive further adoption, while in the UK its gastrointestinal test kits are gaining momentum with National Health Service trusts, supported by positive clinical data and increased usage in infection control and outbreak prevention. The company also continued development of an automated, high-throughput integrated instrument and software platform, including procurement of a non-customised instrument to expand its 3base® infectious disease testing menu, positioning it for future product launches and potential growth in key international markets.
The most recent analyst rating on (AU:GSS) stock is a Sell with a A$0.22 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
Genetic Signatures Limited announced the upcoming departure of CEO Allison Rossiter, who will leave in February 2026 to join a global pharmaceutical company. The company is actively searching for a new CEO and has interim leadership plans in place to ensure continuity. The leadership transition is seen as an opportunity to strengthen the management team and focus on advancing U.S. market opportunities. The recruitment for a new CFO is also underway, highlighting a period of strategic leadership changes aimed at enhancing the company’s capabilities and market positioning.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.